Could a 4-Month TB cocktail replace the standard 6-Month cure?
NCT ID NCT05221502
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 5 times
Summary
This trial tested a new 4-month combination of three drugs (OPC-167832, delamanid, and bedaquiline) against the standard 6-month treatment for drug-susceptible pulmonary tuberculosis. 122 adults with newly diagnosed TB took part. The goal was to see if the shorter regimen is safe and can clear the infection faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPC-167832 combined with delamanid and bedaquiline
- What this could lead to
- If successful, this could lead to a shorter, 4-month treatment for drug-susceptible tuberculosis, reducing the burden of long therapy.
- What could go wrong
- This is an early phase 2 trial with only 122 participants, so results may not confirm safety or effectiveness. The new combination may cause side effects or fail to cure TB as well as the standard 6-month regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aurum Institute - Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
-
Perinatal HIV Research Unit Tshepong Hospital Complex
Klerksdorp, 2574, South Africa
-
Setshaba Research Center
Pretoria, 0152, South Africa
-
TASK Applied Science, Brooklyn Chest Hospital Premises
Cape Town, 7100, South Africa
-
Themba Lethu Clinic Clinical HIV Research Unit (CHRU)
Johannesburg, 2092, South Africa
-
University of CapeTown Lung Center Institute
Cape Town, 7700, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.